Valneva Announces Publication of its COVID-19 Vaccine Phase 3 Data in The Lancet Infectious DiseasesGlobeNewsWire • 09/06/22
Valneva Reports Further Positive Phase 3 Immunogenicity and the First Heterologous Booster Results for its Inactivated, Adjuvanted COVID-19 Vaccine VLA2001GlobeNewsWire • 08/29/22
Valneva Initiates Rolling Submission of FDA Biologics License Application for its Single-Shot Chikungunya Vaccine CandidateGlobeNewsWire • 08/18/22
Valneva Provides Update on IXIARO® Supply Contract with U.S. Department of DefenseGlobeNewsWire • 08/18/22
Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15Business Wire • 08/08/22
Valneva Confirms Amendment of Advance Purchase Agreement with European Commission for Valneva's Inactivated COVID-19 VaccineGlobeNewsWire • 08/01/22
European Commission Approves Purchase Agreement Amendment for Valneva's Inactivated COVID-19 VaccineGlobeNewsWire • 07/20/22
Valneva Receives Marketing Authorization in Europe for Inactivated Whole-Virus COVID-19 Vaccine VLA2001GlobeNewsWire • 06/24/22
Valneva Announces Successful Outcome of its AGM and Appointment of two New Supervisory Board MembersGlobeNewsWire • 06/24/22
Valneva announces resumption of trading of its ordinary shares on Euronext ParisGlobeNewsWire • 06/23/22
Valneva Receives Positive CHMP Opinion for Marketing Authorization of its Inactivated COVID-19 Vaccine Candidate in EuropeGlobeNewsWire • 06/23/22
Valneva SE Sponsored ADR (VALN) Stock Jumps 93.1%: Will It Continue to Soar?Zacks Investment Research • 06/22/22
The Shopify Split Is Just Days Away, but This Tiny Nasdaq Stock Is Soaring Right NowThe Motley Fool • 06/21/22